Episódios
-
Silke Gillessen joins us to discuss the top areas of consensus and controversy from APCCC 2025
-
尿路上皮癌と腎癌の臨床に影響を与えるエビデンスをどう解釈するか!?
-
Estão a faltar episódios?
-
ASCOGU2025で発表された臨床試験の結果の解釈について忖度なしに議論しました！！
-
Tyler Seibert from UCSD joins the show live from Lugano to discuss meeting highlights and controversies (and his favorite run along the water..)
-
Silke joins Tom and Brian to discuss highlights form ASCO GU 2025
-
Toni Choueiri discusses the updated data from different cohorts of this novel HIF inhibitor.
-
Vincent Xu discusses this emerging RCC biomarker and data from the Checkmate 214 trial
-
Gopa Iyer from MSKCC joins the show to discuss his initial results from this phase 2 trial.
-
Matt Galsky joins the show to discuss pCR in NIAGARA and clinical implications.
-
Tanya Dorff from City of Hope joins us to discuss clinical implications of these data and also comment on TALAPRO-2
-
Neeraj Aggarwal joins Tom and Brian for an in-depth look at these important data
-
Silke Gillessen joins Brian and Tom and they discuss what to look forward to in prostate, bladder and RCC at ASCO GU 2025.
-
David Braun joins the show to discuss his Nature paper on a personalized RCC vaccine
-
残念ながらNegative StudyとなったTROPICs-04についてUromigosJapanの3人が忖度なしに、その原因や理由について考察をします！！
-
Shankar Siva joins the show to discuss the emerging role of stereotactic body radiotherapy (SBRT) in primary and metastatic RCC tumors.
-
3人による2024年のGU oncoloyのレビューを切れ味鋭く解説しています。乞うご期待！
-
Tanya Dorff from City of Hope joins Brian and Tom to review what to expect throughout 2025 and beyond in terms of clinically impactful data in prostate, renal and bladder cancer
- Mostrar mais
